FEB 06, 2018 10:56 AM PST

Scientists Use Robotics to Create Effective HIV Vaccines

WRITTEN BY: Kara Marker

Scientists continue to build upon a vaccine candidate to prevent HIV infection, the virus that causes AIDS. AIDSVAX was first developed and tested in the 90s, but now a University of California Santa Cruz scientist is working on perfecting it. Using new robotics technology, researchers are making the vaccine development process more effective and more productive, cutting costs and saving time all the while.

Scanning electromicrograph of an HIV-infected T cell. Credit: NIAID

"Dozens of interesting vaccine candidates have been described, but most have not been tested in humans because it has not previously been possible to manufacture them affordably and in a timely fashion," explained Phil Berman from the University of California Santa Cruz. "The technology we developed should break the logjam in HIV vaccine development, because it tremendously shortens the time, improves the yield, and lowers the cost."

Berman is talking about the multitude of problems many scientists have faced while tackling the production of an effective vaccine to prevent HIV. The virus’s envelope proteins are difficult to imitate and include in a vaccine, which is needed to stimulate the immune system and build immunity against the virus.

Using robotics, Berman and his team were able to make a variety of improvements on the AIDSVAX vaccine and the developmental process:

  1. Decrease the time required to produce stable cell lines, which are necessary for making HIV envelope proteins, an important “ingredient” of an HIV vaccine
  2. Increase the amount of protein the cell lines can produce
  3. Reduce equipment and material costs

Berman was also successful in creating cell lines that make HIV envelope proteins with the right kind of carbohydrate components - glycans - needed for an effective immune response.

"The conventional way of making these envelope protein vaccines incorporated the wrong kind of carbohydrates,” Berman explained. “We now know that destroyed many of the important antigenic sites recognized by protective antibodies."

Glycans are the unique carbohydrates found on HIV envelope proteins. Berman and his team used CRISPR/Cas9 gene editing technology to create a new cell line called “MGAT CHO” that produces the right kind of glycans. Additionally, the process turned out to be simpler and less expensive than others used to recover and purify proteins.

"People used to think carbohydrates are not immunogenic, but HIV turns everything on its head, and it turns out that the most important antibodies are directed to this unusual carbohydrate," Berman said. "We can now make vaccines with it for the first time.”

Berman hopes that the improvements made on the HIV vaccine will improve its efficacy from 31 percent to more than 50 percent. He currently has two cell lines ready to produce vaccines on a large scale, and he is looking for funding to conduct clinical trials.

Sources: aidsmap, University of California Santa Cruz

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 15, 2019
Immunology
SEP 15, 2019
Can Old Cells Have Positive Impacts on MS Patients?
A new study shows that there is a very limited regeneration of cells in the brain of patients diagnosed with multiple sclerosis (MS)....
SEP 15, 2019
Immunology
SEP 15, 2019
Heating Up on the Flu
Climate change may affect the future of vaccinations and nutrition....
SEP 15, 2019
Immunology
SEP 15, 2019
Dengue Meet Immune System
A physical interaction between two types of immune cells that plays an essential role in the early fight against dengue virus infection has been observed for the first time....
SEP 15, 2019
Drug Discovery
SEP 15, 2019
Combination Immunotherapy Stops Liver Cancer Growth
The number of individuals diagnosed with liver cancer is on the rise and current therapies are largely ineffective. However, new preclinical data from the ...
SEP 15, 2019
Immunology
SEP 15, 2019
A Novel Therapeutic Target for a Severe Bacterial Infection
Pseudomonas aeruginosa (Pa) is an opportunistic human pathogen that can cause severe illness and even death in people that are hospitalized or have weakene...
SEP 15, 2019
Cell & Molecular Biology
SEP 15, 2019
Visualizing the Maturation of T Cells in the Thymus
Scientists have visualized how the body tests out important defensive cells, and have captured the process on video....
Loading Comments...